UK MHRA Rectal Catheter Alert: Infant Safety and Post-Market Lessons

This episode examines the UK MHRA's Device Safety Information alert (DSI/2026/008), issued on August 18, 2026, which advises against the use of rectal catheters (gas/colic relievers) in infants. We explore why the MHRA took this precautionary action based on a lack of safety and efficacy data, rather than direct adverse event reports. The discussion focuses on the critical post-market surveillance lessons for manufacturers of direct-to-consumer medical devices, particularly those intended for vulnerable populations like children. Key Questions: - What is the UK MHRA's DSI/2026/008 and why was it issued? - Why are rectal catheters (gas/colic relievers) now considered unsafe for infants in the UK? - What does this alert mean for manufacturers and distributors of direct-to-consumer pediatric devices? - How does this MHRA action highlight the importance of proactive post-market surveillance? - What specific evidence did the MHRA find lacking for these devices? - What are the immediate steps regulatory and quality teams should take in response to this type of alert? - How can you strengthen your clinical data for devices intended for vulnerable populations? - Is this alert based on reported injuries, or is it a precautionary measure? Sources: - https://www.gov.uk/government/publications/rectal-catheters-sold-for-personal-use-gas-and-colic-relievers-do-not-use-in-infants-including-for-the-treatment-of-colic-gas-related-discomfort-or-constipation-dsi2026008 - https://www.rpharms.com/resources/news-and-updates/update-all-rectal-catheters-gas-and-colic-relievers-do-not-use-in-infants How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech companies navigating complex global markets like the UK. Our experts can help you develop a robust post-market surveillance (PMS) and post-market clinical follow-up (PMCF) strategy to ensure your products meet evolving regulatory expectations for safety and efficacy, especially for high-risk or vulnerable populations. We use advanced AI to compile technical dossiers, monitor regulatory changes, and ensure your labeling and clinical evidence are compliant. Whether you need to revise your regulatory strategy or manage submissions, we streamline the process for faster, more reliable market access. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and device database at https://pureglobal.ai.